Quarterly ResultMay 8, 2026, 12:32 PM
AbbVie Q1 Revenue +12.4% to $15.0B; EPS $0.39, down 46%
AI Summary
AbbVie reported mixed first-quarter 2026 results with net revenues increasing 12.4% to $15.002 billion, while net earnings attributable to AbbVie Inc. decreased 46.0% to $695 million, and diluted EPS fell 45.8% to $0.39. The decline in profitability was primarily driven by a significant increase in acquired IPR&D and milestones, including a $650 million upfront payment for a license agreement with RemeGen. Despite this, cash flows from operating activities saw a substantial increase to $3.829 billion.
Key Highlights
- Secured exclusive global license for RC148 from RemeGen with a $650 million upfront payment.
- Net revenues grew 12.4% to $15.002 billion for Q1 2026.
- Net earnings attributable to AbbVie Inc. decreased 46.0% to $695 million.
- Diluted earnings per share fell 45.8% to $0.39.
- Operating earnings increased 6.9% to $3.990 billion.
- Cash flows from operating activities surged to $3.829 billion.
- Issued $8.0 billion in unsecured senior notes in March 2026.
- Declared $3.074 billion in cash dividends during the quarter.
Price Impact
More from ABBV